Description
The global market for prescription respiratory drugs encompasses a wide variety of products that treat both common everyday respiratory illnesses as well as serious chronic conditions such as COPD. Technological developments and improved delivery methods have given many health professionals a wider range of products to treat patients with respiratory diseases and have expanded the market for respiratory pharmaceuticals.
This comprehensive study of the market for prescription pharmaceutical products to treat respiratory illness examines six distinct drug segments:
- Anti-inflammatories, Inhaled Corticosteroids
- Mast Stabilizers, Leukotriene Modifiers, and Other Biologics
- Antihistamines, Decongestants, and Antitussives
- Bronchodilators
- Lung Fluid Replacement and Mucokinetic Agents
- Other Respiratory Drugs
Each section provides particulars on the currently available pharmaceutical products in that class, the development pipeline (including developer and development stage), and detailed market data on the segment, including:
- Historical revenue performance 2000-2005
- Revenue projections through 2010
- Geographic revenue breakdown (U.S. vs non-U.S.)
- Epidemiology of the relevant conditions
- Revenues and market shares of the leading suppliers.
The report also reviews the major drivers and constraints in the respiratory drug market as well as the issues and trends in healthcare more generally that will impact this segment in the coming years and profiles the major competitors in the area, including AstraZeneca, Bayer Corporation, Boehringer Ingelheim, Eli Lilly, Genentech, GlaxoSmithKline, MedImmune, Merck & Co., Pfizer, Sanofi-Aventis, and Schering-Plough.
The information and analysis presented in this report are based on extensive interviews with senior management of top companies in the respiratory drug market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with 42 industry executives and product managers to validate and obtain expert opinion on current and future trends in the respiratory market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.
Table of Contents
chapter one: Executive Summary
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
Chapter Two: Introduction
- Structure and Function of the Respiratory System
- Mechanics of Breathing
- Alterations in Pulmonary Function
- Hypoventilation and Hyperventilation
- Hypoxemia and Hypoxia
Chapter three: Respiratory Diseases
- Obstruction from Conditions in the Wall of the Lumen
- Asthma
- Acute Bronchitis
- Chronic Bronchitis
- Obstructions Related to Loss of Lung Parenchyma
- Obstruction of the Airway Lumen
- Bronchiectasis
- Bronchiolitis
- Cystic Fibrosis
- Croup Syndrome
- Lung Parenchyma Disorders
- Diffuse Interstitial Lung Disease
- Sarcoidosis
- Occupational Lung Diseases
- Infection or Inflammation of the Lung
- Pneumonia
- Severe Acute Respiratory Syndrome
- Lung Cancer
- Respiratory Condition Statistics
chapter Four: Prescription Anti-Inflammatory Agents (Inhaled Corticosteroids)
- Description of Products
- Aerosolized Steroids
- Nasal Sprays
- Products in Research and Development
- Allermist
- Ciclesonide (Alvesco)
- Flutiform
- Market Size and Growth
- Global Market
- U.S. Market Analysis
- Competitive Analysis
Chapter Five: Prescription Mast Cell Stabilizers, Leukotriene Modifiers, and Other Biological Agents
- Description of Products
- Currently Available Products
- Products in Research and Development
- Roflumilast
- PTC 124
- Market Size and Growth
- Global Market
- U.S. Market Analysis
- Competitive Analysis
chapter Six: Prescription Antihistamines, Decongestants, Antitussives, and Combinations
- Description of Products
- Research and Development
- Pantanase
- Xyzal
- Market Size and Growth
- Global Market
- U.S. Market Analysis
- Competitive Analysis
Chapter seven: Prescription Bronchodilators
- Description of Products
- Sympathomimetic Bronchodilators
- Methylxanthine Agents
- Anticholinergic Agents
- Research and Development
- Arformoterol
- Indacaterol
- LAS34273
- Market Size and Growth
- Global Market
- U.S. Market Analysis
- Competitive Analysis
chapter eight: Prescription Lung Fluid Replacement and Mucokinetic Agents
- Description of Products
- Research and Development
- Denufosol
- Market Size and Growth
- Global Market
- U.S. Market Analysis
- Competitive Analysischapter nine: Other Prescription Respiratory Agents
- Description of Products
- Antibiotics
- Cancer Therapy
- Research and Development
- Actimmune
- Aerugen
- Alpha-1 Protease Inhibitor (API)
- Avastin
- Aztreonam
- Cethrymycin
- Erbitux
- Genasense
- Hycamtin Oral
- INS37217 Respiratory
- Javlor
- Lapatinib
- Neovastat
- Nexavar BAY-43-9006
- NOV-002
- Numax
- Oncophage
- Orapem
- Panitumumab
- PF-3512676 (CPG 7909, Promune)
- Talabostat
- Targretin
- Telavancin
- Telcyta
- Tobramycin Dry Powder
- Tocosol
- Tygacil
- Vinorelbine IV
- Xcytrin
- Xorane
- Xyotax
- Zactima
- EDP-420
- Market Size and Growth
- Global Market
- U.S. Market Analysis
- Competitive Analysischapter ten: Issues and Trends
- Patent Loss
- Labeling Changes
- Preferred Drug Listing Problems
- Resistance Issues and Community-acquired Respiratory Infections.
- Bad Air Quality and the Elderly
- New Hope for Emphysema Patients
- Post-approval Drug Studies Mandatory
- Orphan Drugs
- DTC Advertising Turmoil
- Respiratory Drug Delivery
chapter eleven: Total Market Summary
- Overview
- Market Analysis
- Competitor Analysis
chapter twelve: Competitor Profiles
- AstraZeneca PLC
- Bayer Corporation
- Boehringer Ingelheim GmbH
- Eli Lilly and Company
- Genentech, Inc.
- GlaxoSmithKline plc
- MedImmune, Inc.
- Merck & Company, Inc.
- Pfizer, Inc.
- Sanofi-Aventis
- Schering-Plough Corporation
Appendix: Company Directory
List of Exhibits
chapter one: Executive Summary
- Figure 1-1: Market Summary: World Market for Prescription Respiratory Drugs 2000-2010
- Table 1-1: World Market for Respiratory Drugs; Revenues and Market Share by Leading Participants 2005
Chapter three: Respiratory Diseases
- Table 3-1: Worldwide Prevalence of Selected Respiratory Conditions
- (Asthma, Bronchitis, Emphysema, Cystic Fibrosis, Lung Cancer, Allergic Rhinitis, Influenza, COPD)
chapter Four: Prescription Anti-Inflammatory Agents (Inhaled Corticosteroids)
- Table 4-1: Prescription Anti-inflammatory Agents in Development (Product, Indication, Developer, Phase)
- Table 4-2: The World Market for Prescription Anti-inflammatory Agents
- Revenues and Growth Rates 2000-2010
- Figure 4-1: Trending in the World Market for Prescription Anti-Inflammatory Agents 2000-2010
- Table 4-3: The U.S. Market for Prescription Anti-inflammatory Agents
- Revenues and Share of World Market 2000-2010
- Figure 4-2: Trending in the U.S. Market for Prescription Anti-inflammatory
- Agents 2000-2010
- Table 4-4: The World Market for Prescription Anti-inflammatory Agents
- Revenues and Market Share by Leading Supplier 2005
Chapter Five: Prescription Mast Cell Stabilizers, Leukotriene Modifiers, and Other Biological Agents
- Table 5-1: Prescription Mast Cell Stabilizers, Leukotriene Modifiers, and
- Other Biologic Agents in Development (Product, Indication,
- Developer, Phase)
- Table 5-2: The World Market for Prescription Mast Stabilizers, Leukotriene Modifiers and Other Biologics, Revenues and Growth Rates
- 2000-2010
- Figure 5-1: Trensing in the World Market for Prescription Mast Stabilizers, Leukotriene Modifiers and Other Biologics 2000-2010
- Table 5-3: The U.S. Market for Prescription Mast Stabilizers, Leukotriene
- Modifiers and Other Biologics Revenues and Share of World
- Market 2000-2010
- Figure 5-2: Trending in the U.S. Market for Prescription Mast Stabilizers, Leukotriene Modifiers and Other Biologics 2000-2010
- Table 5-4: The World Market for Prescription Mast Stabilizers, Leukotriene Modifiers and Other Biologics Revenues and Market Share by
- Leading Supplier 2005
chapter Six: Prescription Antihistamines, Decongestants, Antitussives, and Combinations
- Table 6-1: Prescription Antihistamines, Decongestants, and Combinations in Development (Product, Indication, Developer, Phase)
- Table 6-2: The World Market for Prescription Antihistamines and Decongestants, Revenues and Growth Rates 2000-2010
- Figure 6-1: Trending in the World Market for Prescription Antihistamines and Decongestants 2000-2010
- Table 6-3: The U.S. Market for Prescription Antihistamines and Decongestants, Revenues and Share of World Market 2000-2010
- Figure 6-2: Trending in the U.S. Market for Prescription Antihistamines and Decongestants 2000-2010
- Table 6-4: The World Market for Prescription Antihistamines and Decongestants, Revenues and Market Share by Leading Supplier 2005
Chapter seven: Prescription Bronchodilators
- Table 7-1: Prescription Bronchodilators in Development (Product, Indication, Developer, Phase)
- Table 7-2: The World Market for Prescription Bronchodilators Revenues and Growth Rates 2000-2010
- Figure 7-1: Trending in the World Market for Prescription Bronchodilators 2000-2010
- Table 7-3: The U.S. Market for Prescription Bronchodilators Revenues and
- Share of World Market 2000-2010
- Figure 7-2: Trending the U.S. Market for Prescription Bronchodilators
- 2000-2010
- Table 7-4: The World Market for Prescription Bronchodilators Revenues and Market Share by Leading Supplier 2005
chapter eight: Prescription Lung Fluid Replacement and Mucokinetic Agents
- Table 8-1: Prescription Lung Fluid Replacement and Mucokinetic Agents in Development (Product, Indication, Developer, Phase)
- Table 8-2: The World Market for Prescription Lung Fluid Replacement and Mucokinetic Agents Revenues and Growth Rates 2000-2010
- Figure 8-1: Trending in the World Market for Prescription Lung Fluid
- Replacement and Mucokinetic Agents 2000-2010
- Table 8-3: The U.S. Market for Prescription Lung Fluid Replacement and Mucokinetic Agents Revenues and Share of World Market
- 2000-2010
- Figure 8-2: Trending in the U.S. Market for Prescription Lung Fluid
- Replacement and Mucokinetic Agents 2000-2010
- Table 8-4: The World Market for Prescription Lung Fluid Replacement and Mucokinetic Agents, Revenues and Market Share by Leading
- Supplier 2005
chapter nine: Other Prescription Respiratory Agents
- Table 9-1: Other Prescription Respiratory Agents in Development (Product, Indication, Developer, Phase)
- Table 9-2: The World Market for Other Prescription Respiratory Drugs
- Revenues and Growth Rates 2000-2010
- Figure 9-1: Trending in the World Market for Other Prescription Respiratory
- Drugs 2000-2010
- Table 9-3: The U.S. Market for Other Prescription Respiratory Drugs
- 2000-2010
- Figure 9-2: Trending in the U.S. Market for Other Prescription Respiratory
- Drugs 2000-2010
- Table 9-4: The World Market for Other Prescription Respiratory Drugs
- Revenues and Market Share by Leading Supplier 2005
chapter eleven: Total Market Summary
- Table 11-1: The World Market for Respiratory Drugs, Revenues by Segment
- 2000-2010
- Figure 11-1: Trending in the World Market for Respiratory Drugs by Segment 2000-2010
- Table 11-2: World Market for Prescription Respiratory Drugs Revenues and Segments of Participation of Leading Suppliers 2005
- Figure 11-2: World Market for Prescription Respiratory Drugs Market
- Share by Leading Supplier, 2005
